We are pleased to announce that our Director of Radiopharmaceuticals, Dr Wing Kwong Sidney Yu, has been admitted as a Fellow of the Institute of Biomedical Science (FIBMS),
Dr Sidney Yu
PhD, FRSC, FIBMS
The Fellowship of the Royal Society of Chemistry (FRSC) and the Institute of Biomedical Science (FIBMS) are among the most prestigious professional recognitions awarded in the United Kingdom. Conferred by the Royal Society of Chemistry (RSC) and the Institute of Biomedical Science (IBMS) respectively, these fellowships are held by distinguished scientists, including Nobel Prize winners, leading innovators, and influential contributors to global scientific and biomedical research.
Dr Sidney has been instrumental in the development of radiochemistry and nuclear medicine in Singapore and Southeast Asia. A senior and highly respected radiochemist, he established Singapore’s first GMP compliant cyclotron and radiochemistry laboratory, attracting major investments from multinational pharmaceutical companies such as Roche, Bayer, and Merck. He has driven key advances in targeted radionuclide therapies, including Selective Internal Radiation Therapy (SIRT), the first radiochemo embolization therapy for unresectable liver cancer, and the introduction of Peptide Receptor Radionuclide Therapy (PRRT). Since joining SAM in 2018 as Director of Radiopharmaceuticals, Dr Sidney has built the radiopharmaceutical laboratory from the ground up, led the introduction of novel radiotracers with strong clinical potential including N-13 ammonia and Ac-225 PSMA and positioned SAM as one of the few centres in Southeast Asia capable of producing short half-life radiotracers and serving as a trusted clinical research partner for global theranostics development.
He has been admitted as a Fellow in recognition of his outstanding contributions to radiochemistry and nuclear medicine in Singapore and Southeast Asia. A senior and highly respected radiochemist, he established Singapore’s first GMP-compliant cyclotron and radiochemistry laboratory, attracting major investments from multinational pharmaceutical companies such as Roche, Bayer, and Merck.
He has driven key advances in targeted radionuclide therapies, including Selective Internal Radiation Therapy (SIRT) the first radiochemo embolization therapy for unresectable liver cancer and the introduction of Peptide Receptor Radionuclide Therapy (PRRT). Since joining SAM in 2018 as Director of Radiopharmaceuticals, Dr Sidney has built the radiopharmaceutical laboratory from the ground up, led the introduction of novel radiotracers with strong clinical potential including N-13 ammonia and Ac-225 PSMA and positioned SAM as one of the few centres in Southeast Asia capable of producing short half-life radiotracers and serving as a trusted clinical research partner for global theranostics development.
This fellowship acknowledges Dr Sidney Yu’s leadership, innovation, and dedication to advancing biomedical science in the region.
Heartiest congratulations Dr Sidney from management, doctors and staff of Singapore Institute of Advanced Medicine Holdings.
